Stability Indicating Method for the Assay of Remogliflozin Etabonate and its Related Substances by RP-HPLC

被引:3
作者
Yadav, Ramji Lal [1 ]
Dev, Rahul [1 ]
Santra, Ruchita [2 ]
Jain, Priti [2 ]
机构
[1] Mankind Res Ctr, Manesar, Gurugram, India
[2] Delhi Pharmaceut Sci & Res Univ, Sch Pharmaceut Sci, Dept Pharmaceut Chem, New Delhi 110017, India
关键词
Remogliflozin Etabonate (RME); related substances; assay; gradient; HPLC; INHIBITOR;
D O I
10.1080/22297928.2023.2176785
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Simple, accurate, precise and stable indicating HPLC methods were developed and validated to determine both related substances and the assay content of Remogliflozin etabonate (RME). The separation was established under optimized chromatographic condition using Waters e2695 HPLC coupled to Ultraviolet detector (UV) at 228 nm with Inertsil ODS-3V C18 column (250 mm x 4.6 mm, 5 & mu;m), injection volume 10 & mu;l for related substances and 20 & mu;l for assay content determination. The mobile phase consisted of 10 mM KH2PO4 buffer with ortho-phosphoric acid pH 2.5. Gradient elution was maintained at a flow rate of 1.0 ml/min using 45 & DEG;C column oven temperature for determination of the related substances and isocratic elution was maintained at a flow rate of 1.2 ml/min for assay content. The retention time for RME-01, RME-02, RME-03 and RME-04, RME-05 and RME were about 41.74 min, 11.42 min, 20.38 min, 37.16 min, 49.93 min, 25.05 min respectively. The linearity was found to be in the concentration range of 0.312-2.341 & mu;g/ mL for RME-01, 0.306-2.292 & mu;g/ mL for RME-02, 0.306-2.297 & mu;g/ ml for RME-03 and 0.294-2.203 & mu;g/mL for RME-04. The RME was subjected to acid, base, oxidation, and thermal degradation stress conditions. The method was validated according to the ICH guidelines for specificity, precision, linearity, accuracy and robustness and the values were found to be within the limits.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 12 条
[11]   Stability indicating liquid chromatographic method for the estimation of remogliflozin etabonate [J].
Shah, Dimal A. ;
Gondalia, Ishita I. ;
Patel, Vandana B. ;
Mahajan, Ashok ;
Chhalotiya, Usmangani K. .
JOURNAL OF CHEMICAL METROLOGY, 2020, 14 (02) :125-132
[12]   Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies [J].
Sigafoos, James F. ;
Bowers, Gary D. ;
Castellino, Stephen ;
Culp, Amanda G. ;
Wagner, David S. ;
Reese, Melinda J. ;
Humphreys, Joan E. ;
Hussey, Elizabeth K. ;
Semmes, Robin L. O'Connor ;
Kapur, Anita ;
Tao, Wenli ;
Dobbins, Robert L. ;
Polli, Joseph W. .
DRUG METABOLISM AND DISPOSITION, 2012, 40 (11) :2090-2101